Trials / Unknown
UnknownNCT04997252
An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Zhujiang Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The neoadjuvant therapy with apalutamide can significantly improve the prognosis of patients with high-risk and oligometastatic prostate cancer, lower the rate of positive margins, reduce recurrence, and show high safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apalutamide | apalutamide as neoadjuvant therapy |
Timeline
- Start date
- 2021-02-01
- Primary completion
- 2024-08-01
- Completion
- 2024-12-01
- First posted
- 2021-08-09
- Last updated
- 2024-03-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04997252. Inclusion in this directory is not an endorsement.